Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
Abnormal activation of the Wnt/beta-catenin pathway observed in malignant tumors has been an attractive target pathway for anticancer therapeutics. In the present study, we studied action mechanism of IMU14 derivatives that we identified as inhibitors of Wnt/beta-catenin pathway. We hypothesized that IMU compounds switch proteasomal beta-catenin degradation to lysosomal proteoyisis, and verified the hypothesis. In addition to in vitro studies, antitumor activity of an IMU compound was analyzed in a dextran sulfate-induced colorectal tumor model in APCMin/+ mice.
|